Dianthus Therapeutics, Inc. (DNTH) vs Travere Therapeutics, Inc. (TVTX)
Dianthus Therapeutics, Inc. and Travere Therapeutics, Inc. are both Biotechnology companies. Travere Therapeutics, Inc. is the larger, with a market value of $5.7B against $5.1B — 1.1× the size. Travere Therapeutics, Inc. grew revenue faster over the last twelve months: 77.1% against −60.8%. Travere Therapeutics, Inc. has the higher net margin (−7.35% vs −10,097.0%) and the higher return on invested capital (−18.3% vs −47.7%). Across the 17 metrics below, Travere Therapeutics, Inc. leads on 11 and Dianthus Therapeutics, Inc. on 6.
Valuation
Profitability
| Metric | DNTH | TVTX | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 98.60% | 65.16% |
| Operating margin | (11,441.39%) | (6.84%) | 0.00% |
| Net margin | (10,096.95%) | (7.35%) | 0.00% |
| Free cash flow margin | (8,177.99%) | 2.56% | 0.00% |
| Return on equity | (26.07%) | (151.79%) | (57.72%) |
| Return on assets | (24.98%) | (6.42%) | (49.22%) |
| Return on invested capital | (47.74%) | (18.31%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack